MX390748B - Composiciones y metodos para tratar accidente cerebrovascular isquemico. - Google Patents

Composiciones y metodos para tratar accidente cerebrovascular isquemico.

Info

Publication number
MX390748B
MX390748B MX2018006390A MX2018006390A MX390748B MX 390748 B MX390748 B MX 390748B MX 2018006390 A MX2018006390 A MX 2018006390A MX 2018006390 A MX2018006390 A MX 2018006390A MX 390748 B MX390748 B MX 390748B
Authority
MX
Mexico
Prior art keywords
sub
sup
methods
compositions
treating ischemic
Prior art date
Application number
MX2018006390A
Other languages
English (en)
Spanish (es)
Other versions
MX2018006390A (es
Inventor
David Elmaleh
Original Assignee
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Gen Hospital filed Critical Massachusetts Gen Hospital
Publication of MX2018006390A publication Critical patent/MX2018006390A/es
Publication of MX390748B publication Critical patent/MX390748B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2018006390A 2015-11-23 2016-11-23 Composiciones y metodos para tratar accidente cerebrovascular isquemico. MX390748B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562258882P 2015-11-23 2015-11-23
PCT/US2016/063462 WO2017091644A1 (en) 2015-11-23 2016-11-23 Compositions and methods for treating ischemic stroke

Publications (2)

Publication Number Publication Date
MX2018006390A MX2018006390A (es) 2019-02-14
MX390748B true MX390748B (es) 2025-03-21

Family

ID=58764360

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006390A MX390748B (es) 2015-11-23 2016-11-23 Composiciones y metodos para tratar accidente cerebrovascular isquemico.

Country Status (9)

Country Link
US (2) US20180344682A1 (enExample)
EP (1) EP3380095B1 (enExample)
JP (1) JP2018538273A (enExample)
KR (1) KR20180081812A (enExample)
CN (1) CN108472275A (enExample)
AU (1) AU2016359674A1 (enExample)
CA (1) CA3005909A1 (enExample)
MX (1) MX390748B (enExample)
WO (1) WO2017091644A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US9855276B2 (en) 2012-10-25 2018-01-02 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP3506894B1 (en) * 2016-08-31 2023-08-23 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
WO2019017995A1 (en) 2017-07-20 2019-01-24 Aztherapies, Inc. FORMULATIONS OF CROMOLYNE SODIUM POWDER AND IBUPROFEN
JP2021505658A (ja) * 2017-12-04 2021-02-18 ザ ジェネラル ホスピタル コーポレイション クロモリン組成物及びその方法
CA3096545A1 (en) * 2018-04-09 2019-10-17 The General Hospital Corporation Combination therapies for the treatment of amyotropic lateral sclerosis and related disorders
JP2021529771A (ja) 2018-07-02 2021-11-04 ザ ジェネラル ホスピタル コーポレイション クロモリンナトリウムおよびα−ラクトースの粉末製剤
US12383528B2 (en) 2018-12-10 2025-08-12 The General Hospital Corporation Cromolyn esters and uses thereof
JP2023520580A (ja) 2020-04-06 2023-05-17 ザ ジェネラル ホスピタル コーポレイション コロナウイルス誘発炎症状態の処置方法
WO2022146914A1 (en) 2020-12-28 2022-07-07 The General Hospital Corporation Cromolyn derivatives and uses thereof
WO2025235823A1 (en) * 2024-05-08 2025-11-13 The Johns Hopkins University Compositions and methods for treatment of neuronal injury and neurode generative disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071531A1 (en) * 2003-02-13 2004-08-26 Licentia Oy Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
KR101414810B1 (ko) * 2004-08-30 2014-07-18 주식회사 유스팜인터내셔널 국소 허혈 모델에서의 가용화 ｕｄｃａ의 신경보호 효과
CA2751125C (en) 2009-01-29 2017-06-20 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US9925282B2 (en) * 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
TW201613969A (en) * 2009-03-05 2016-04-16 Abbvie Inc IL-17 binding proteins
EP2406260A1 (en) * 2009-03-11 2012-01-18 Plexxikon, Inc. Pyrrolo [2, 3-b]pyridine derivatives for the inhibition of raf kinases
US9855276B2 (en) * 2012-10-25 2018-01-02 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
WO2015002703A1 (en) * 2013-05-23 2015-01-08 Aztherapies, Inc Methods for delivering cromolyn
AU2014340182B2 (en) * 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CA2938994A1 (en) * 2014-02-10 2015-08-13 Patara Pharma, LLC Inhalable formulations of sodium cromolyn with improved bioavailability
EP3506894B1 (en) * 2016-08-31 2023-08-23 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases

Also Published As

Publication number Publication date
KR20180081812A (ko) 2018-07-17
WO2017091644A1 (en) 2017-06-01
US20220125753A1 (en) 2022-04-28
EP3380095B1 (en) 2022-01-05
AU2016359674A1 (en) 2018-06-14
EP3380095A1 (en) 2018-10-03
MX2018006390A (es) 2019-02-14
JP2018538273A (ja) 2018-12-27
CA3005909A1 (en) 2017-06-01
CN108472275A (zh) 2018-08-31
US20180344682A1 (en) 2018-12-06
EP3380095A4 (en) 2019-10-23

Similar Documents

Publication Publication Date Title
MX2018006390A (es) Composiciones y metodos para tratar accidente cerebrovascular isquemico.
EA201890522A1 (ru) Способ получения противогрибковых соединений
MX388682B (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
UY40612A (es) Piridinas sustituidas con heteroarilo y métodos de uso
PE20190395A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
EA202091505A1 (ru) Триазолазолы циклогексильной кислоты в качестве антагонистов lpa
MX378499B (es) Compuestos antifungicos.
EA201691156A1 (ru) Пирролидиноновые гербициды
DOP2016000299A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1
EA201691439A1 (ru) Пиримидинилоксибензольные производные в качестве гербицидов
ECSP16067303A (es) Heteroarilos y usos de estos
EA201591497A1 (ru) Новые производные октагидропирроло[3,4-c]пиррола и их аналоги в качестве ингибиторов аутотаксина
MX376833B (es) Oxiesteroles y metodos de uso de los mismos.
EP3331880A4 (en) N- (PYRIDIN-2-YL) -4- (THIAZOL-5-YL) PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
TN2018000020A1 (en) Colony stimulating factor-1 receptor (csf-1r) inhibitors.
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
MX388321B (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
EA201792433A1 (ru) Производные 2-(фенилокси- или фенилтио)пиримидина в качестве гербицидов
MX381344B (es) Compuestos antifungicos y procesos para la fabricacion.
MX382122B (es) Oxiesteroles y metodos de uso de los mismos.
NZ759764A (en) Glucuronide prodrugs of janus kinase inhibitors
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
UY36564A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac